Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead 
Welcome,         Profile    Billing    Logout  
 0 Diseases   10 Trials   10 Trials   41 News 


«12...15161718192021222324252627»
  • ||||||||||  Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    Trial completion date, Trial primary completion date:  B/F/TAF vs Atripla Double-Blind Switch Study in HIV-1 Infected Adults (clinicaltrials.gov) -  Apr 19, 2020   
    P4,  N=200, Recruiting, 
    Trial completion date: Jan 2020 --> Oct 2021 | Trial primary completion date: Dec 2019 --> Sep 2021
  • ||||||||||  azithromycin / Pfizer, Generic mfg., Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    The Great Mimicker Unveiled: A Case of Membranous Nephropathy from Syphilis () -  Mar 27, 2020 - Abstract #NKFCSM2020NKF_CSM_373;    
    Secondary syphilis is associated with nephrotic syndrome due to membranous nephropathy and recovery after treatment with penicillin. With the recent epidemiology of STDs, clinicians must be vigilant of syphilis involvement in nephropathy and should consider it in the differential diagnosis of nephrotic syndrome.
  • ||||||||||  emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
    Multi-System Kaposi Sarcoma with Bronchopulmonary Involvement (PENNSYLVANIA CONVENTION CENTER, Hall D-E (200 Level), Area A) -  Mar 15, 2020 - Abstract #ATS2020ATS_8943;    
    He responded well to treatment, completing 6 cycles of chemotherapy. He is now maintained on HAART (bictegravir, emtricitabine, and tenofovir alafenamide) and doing well.
  • ||||||||||  Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    New P4 trial:  Biktarvy in Treatment-Na (clinicaltrials.gov) -  Mar 5, 2020   
    P4,  N=250, Not yet recruiting, 
  • ||||||||||  lamivudine / Generic mfg.
    [VIRTUAL] HIV VIRAL BLIPS IN ADULTS TREATED WITH InSTI-BASED REGIMENS THROUGH 144 WEEKS ([VIRTUAL]) -  Mar 2, 2020 - Abstract #CROI2020CROI_1241;    
    Blips 200 c/mL but not <200 c/mL were associated with adherence 95%. High level blips of 200 c/mL were associated with lower suppression at week 144 due to poor adherence; however, none developed resistance on these 3-drug regimens with high barriers to resistance.
  • ||||||||||  Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    [VIRTUAL] B/F/TAF LOW-DOSE TABLET RELATIVE BIOAVAILABILITY IN HVs AND PK IN CHILDREN WITH HIV ([VIRTUAL]) -  Mar 2, 2020 - Abstract #CROI2020CROI_1007;    
    Bictegravir (BIC)/emtricitabine (FTC)/tenofovir alafenamide (B/F/TAF 50/200/25 mg) single tablet regimen (bilayer tablet) is FDA-approved for the treatment of HIV in adults and pediatrics 25 kg...Like the adult tablet, LDT can be taken without regard to food. In children 14-< 25kg with HIV taking the LDT, no clinically meaningful differences in PK were identified compared to adults; mean BIC Ctau was 12-fold above paEC95, supporting its continued evaluation in pediatric trials.
  • ||||||||||  Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    [VIRTUAL] SAFETY, PK, AND EFFICACY OF LOW DOSE B/F/TAF IN CHILDREN ≥2 YEARS OLD LIVING WITH HIV ([VIRTUAL]) -  Mar 2, 2020 - Abstract #CROI2020CROI_1006;    
    STR of bictegravir, emtricitabine and tenofovir alafenamide (B/F/TAF) is approved for use in HIV-infected children weighing 25 kg...Efficacy and safety of the pediatric STR in young children are consistent with adult strength STR efficacy in older populations. These data support further evaluation of low dose B/F/TAF as an unboosted INSTI-based STR for young children living with HIV.
  • ||||||||||  Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    [VIRTUAL] SAFETY AND TOLERABILITY OF ONCE-DAILY BIC/FTC/TAF FOR POSTEXPOSURE PROPHYLAXIS ([VIRTUAL]) -  Mar 2, 2020 - Abstract #CROI2020CROI_693;    
    The fixed drug combination of bictegravir, emtricitabine, tenofovir alafenamide appears to be safe and well-tolerated when used as PEP, with occasional, mainly mild, gastrointestinal side effects, fatigue, and infrequent laboratory abnormalities. This favorable safety profile, and the high completion rates, suggest that BIC/FTC/TAF is a potential option for PEP.
  • ||||||||||  Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    [VIRTUAL] PREEXISTING RESISTANCE AND B/F/TAF SWITCH EFFICACY IN AFRICAN AMERICANS ([VIRTUAL]) -  Mar 2, 2020 - Abstract #CROI2020CROI_511;    
    The BRAAVE 2020 study is evaluating the safety and efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) among virologically suppressed adults with HIV in the US who identify as Black or African American...Pre-existing resistance was common among suppressed Black Americans switching to B/F/TAF, notably M184V/I, TAMs, and NNRTI-R. High rates of virologic suppression were maintained through 24 weeks of B/F/TAF treatment and there were no failures with resistance, indicating that B/F/TAF is an effective treatment option for patients with or without pre-existing resistance to NNRTIs, PIs, or non-tenofovir NRTIs.
  • ||||||||||  lamivudine / Generic mfg.
    [VIRTUAL] 144-WEEK EFFICACY AND SAFETY OF B/F/TAF IN TREATMENT-NAIVE ADULTS ≥50 YRS ([VIRTUAL]) -  Mar 2, 2020 - Abstract #CROI2020CROI_504;    
    We conducted two randomized, double blind, phase 3 studies of B/F/TAF in treatment-naïve adults, Study 1489: B/F/TAF vs dolutegravir, abacavir, and lamivudine (DTG/ABC/3TC) and Study 1490: B/F/TAF vs DTG + F/TAF...Through three years of treatment, B/F/TAF was highly effective, safe and well tolerated in adults 50 yrs with no clinically significant impact on bone or renal safety, fasting lipids or weight. B/F/TAF provides a safe and effective treatment option for older adults with a low potential for drug-drug interactions.
  • ||||||||||  Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    [VIRTUAL] RANDOMIZED SWITCH TO B/F/TAF IN AFRICAN AMERICAN ADULTS WITH HIV ([VIRTUAL]) -  Mar 2, 2020 - Abstract #CROI2020CROI_158;    
    The proportion with HIV-1 RNA For Black Americans, switching to B/F/TAF was noninferior to continuing their regimen with high efficacy in both arms. The single-tablet regimen B/F/TAF was safe and effective for people switching from a variety of regimens, including those with pre-existing NRTI resistance, and was associated with greater treatment satisfaction.
  • ||||||||||  BacWGSTdb 2.0: a one-stop platform for bacterial whole-genome sequence typing and source tracking (HALL F) -  Feb 4, 2020 - Abstract #ECCMID2020ECCMID_4140;    
    Not yet recruiting --> Recruiting BacWGSTdb 2.0 is expected to provide a one-stop solution to epidemiological outbreak analysis of both hospital and foodborne bacterial pathogens for epidemiologists, clinicians and bench scientists and has the potential to add value for WGS moving from proof-of-concept studies to routine use in the clinical microbiology laboratory.
  • ||||||||||  Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    Enrollment open, Adverse events:  DOBINeuro: Neurological Monitoring in Patients Switching From Dolutegravir Based Regimen to Bictegravir Based Regimen (clinicaltrials.gov) -  Jan 30, 2020   
    P3,  N=100, Recruiting, 
    BacWGSTdb 2.0 is expected to provide a one-stop solution to epidemiological outbreak analysis of both hospital and foodborne bacterial pathogens for epidemiologists, clinicians and bench scientists and has the potential to add value for WGS moving from proof-of-concept studies to routine use in the clinical microbiology laboratory. Not yet recruiting --> Recruiting
  • ||||||||||  Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead, NN1213 / Novo Nordisk
    Enrollment closed, Enrollment change:  Early ART to Limit Infection and Establishment of Reservoir (clinicaltrials.gov) -  Jan 27, 2020   
    P2,  N=195, Active, not recruiting, 
    Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=150 --> 195
  • ||||||||||  Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    Trial primary completion date:  Effects of Biktarvy on CFR in Stable HIV Patients (clinicaltrials.gov) -  Jan 18, 2020   
    P3,  N=30, Recruiting, 
    Active, not recruiting --> Completed Trial primary completion date: Nov 2019 --> Nov 2020
  • ||||||||||  Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    @BIKTARVY @GileadSciences (Twitter) -  Jan 3, 2020   
  • ||||||||||  Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    Enrollment open, Trial completion date, Trial primary completion date:  Optimizing the Delivery of HIV nPEP (clinicaltrials.gov) -  Dec 20, 2019   
    P2,  N=318, Recruiting, 
    Trial completion date: Jun 2019 --> Jun 2021 | Trial primary completion date: Jun 2019 --> Jul 2020 Not yet recruiting --> Recruiting | Trial completion date: Dec 2019 --> May 2022 | Trial primary completion date: Dec 2019 --> Jan 2022